A new study has for the first time elucidated the gut-liver immune regulatory axis jointly maintained by intestinal commensal bacteria and the intestinal endocrine system, and uncovered the ...

While the United States and Europe are moving cautiously forward with clinical trials, China is racing toward the commercialization of brain implants.

The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in China.

The planned Shanghai facility extends a yearslong push into the field and will support CAR-T therapies AstraZeneca is making for autoimmune disease and cancer.

AstraZeneca said on Thursday it would build a cell therapy ​manufacturing and supply base and an innovation centre ‌in Shanghai, aiming to become the first global drugmaker with end-to-end cell ...

Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...

In 2021, a global tuberculosis vaccine research and development roadmap proposed a series of actions to accelerate the development of new, effective, and affordable vaccines that are urgently needed ...

At first glance this was huge news with chemical implications: $300 billion would be an extraordinary investment for a refinery, many times more than was put into China’s giant Zhejiang Petroleum and ...

Penn Engineers have redesigned the lipid nanoparticles (LNPs) used to deliver mRNA vaccines, showing that subtle changes in lipid chemistry can influence immune cell metabolism and reduce inflammation ...

IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's proprietary mRNA-LNP platform.HONG KONG SAR ...